Volume 33, Issue 1 (April 2022)                   Studies in Medical Sciences 2022, 33(1): 1-7 | Back to browse issues page

Ethics code: IR.UMSU.REC.1399.121

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

URL: http://umj.umsu.ac.ir/article-1-5770-en.html
Assistant professor, Department of pediatrics, Faculty of medicine, Urmia University of Medical Sciences, urmia, Iran. , gazizadef@gmail.com
Abstract:   (1549 Views)
Background & Aims: Febrile Neutropenia (FN) is one of the common complications of chemotherapy in the children with malignancy. In this study, we investigated the effective factors in response to the treatment of patients with febrile neutropenia. By using these factors, it is possible to have a better analysis about the severity of infection of these patients and it will helpful in choosing the right antibiotic.
Materials & Methods: In this cross-sectional study, children with acute lymphoblastic leukemia (ALL) who underwent chemotherapy during the last 10 years and were hospitalized due to febrile neutropenia were included in the study. The patients had no known source of infection and fever and all were treated with the same antibiotics.
Results: The mean age of the patients was 9.13 ± 3.84 years. The mean hospitalization period of the patients was 10 days, and 9 (7.1%) of the patients were admitted to the ICU. 25 (20.5%) of the hospitalized patients had died. The amount of ESR had a significant effect on the number of days with fever, and with an increase of one ESR unit, the chance of fever continuing for more than 5 days increased by 1.02%. The number of platelets at the time of hospitalization was identified as one of the factors affecting the death of patients, and the odds ratio of death in the patients with a platelet count of ≤50,000 was higher than that of people with a platelet count >50,000.
Discussion: Increased CRP and thrombocytopenia at the beginning of hospitalization are among the predictors of bad prognosis in the patients with febrile neutropenia.
Full-Text [PDF 422 kb]   (716 Downloads)    

1. Badr M, Hassan T, Sakr H, Karam N, Rahman DA, Shahbah D, et al. Chemotherapy induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences. Mol Clin Oncol 2016;5(3):300-6. [DOI:10.3892/mco.2016.957] [PMID] [PMCID]
2. Rackoff WR, Gonin R, Robinson C, Kreissman SG, Breitfeld PB. Predicting the risk of bacteremia in childen with fever and neutropenia. J Clin Oncol 1996;14(3):919-24. [DOI:10.1200/JCO.1996.14.3.919] [PMID]
3. Klaassen RJ, Goodman TR, Pham BA, Doyle JJ. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000;18(5):1012. [DOI:10.1200/JCO.2000.18.5.1012] [PMID]
4. Hakim H, Flynn PM, Srivastava DK, Knapp KM, Li C, Okuma J, et al. Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 2010;29(1):53-9. [DOI:10.1097/INF.0b013e3181c3f6f0] [PMID]
5. Adamson PC. Improving the outcome for children with cancer: development of targeted new agents. CA Cancer J Clin 2015;65(3):212-20. [DOI:10.3322/caac.21273] [PMID] [PMCID]
6. Talcott JA. Assessing risk in cancer patients with fever and neutropenia. In: Febrile Neutropenia. Springer; 1997.p.23-7. [DOI:10.1007/978-3-642-60443-0_5]
7. Aquino VM, Tkaczewski I, Buchanan GR. Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clin Infect Dis 1997;25(1):74-8. [DOI:10.1086/514512] [PMID]
8. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer Interdiscip Int J Am Cancer Soc 1999;86(1):126-34. https://doi.org/10.1002/(SICI)1097-0142(19990701)86:1<126::AID-CNCR18>3.0.CO;2-1 [DOI:10.1002/(SICI)1097-0142(19990701)86:13.0.CO;2-1]
9. Chaudhary N, Kosaraju K, Bhat K, Bairy I, Borker A. Significance of interleukin-6 (IL-6) and C-reactive protein (CRP) in children and young adults with febrile neutropenia during chemotherapy for cancer: a prospective study. J Pediatr Hematol Oncol 2012;34(8):617-23. [DOI:10.1097/MPH.0b013e3182677fc6] [PMID]
10. Šegulja S, Ružić A, Dujmić D, Baždarić K, Roganović J. Simple predictors of the re-occurrence of severe febrile neutropenia episode: a single-center retrospective cohort study in pediatric patients with malignant diseases. Croat Med J 2019;60(1):20. [DOI:10.3325/cmj.2019.60.20] [PMID] [PMCID]
11. Ortega, M., Rovira, M., Almela, M. et al. Measurement of C-reactive protein in adults with febrile neutropenia after hematopoietic cell transplantation. Bone Marrow Transplant 2004;33:741-4. [DOI:10.1038/sj.bmt.1704409] [PMID]
12. Gurlinka S, Kini P, Aroor S, Mundkur S. Factors Associated with Adverse Outcome in Pediatric Febrile Neutropenia: Results from a Tertiary Care Hospital. Int J Pediatr 2017;5(12):6447-55. [URL]
13. Moon JM, Chun BJ. Predicting the complicated neutropenic fever in the emergency department. Emerg Med J 2009;26(11):802-6. [DOI:10.1136/emj.2008.064865] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Studies in Medical Sciences

Designed & Developed by : Yektaweb